Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KITE 439

Next Previous
X
Search
Drug Profile

KITE 439

Alternative Names: Anti HPV E7 TCR; anti-HPV016 E7 TCR; E7 TCR gene therapy; E7-TCR; HPV-16 E7 TCR; KITE-439

Latest Information Update: 06 Jun 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Cancer Institute (USA)
  • Developer Kite Pharma; National Cancer Institute (USA)
  • Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cancer; Solid tumours

Most Recent Events

  • 02 Mar 2022 Kite Pharma terminates phase I trial in Cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in the US (NCT03912831)
  • 15 Nov 2021 Discontinued - Phase-I for Cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (IV)
  • 15 Nov 2021 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top